SCHEMBL6712644

SCHEMBL6712644

Oc1ccccc1C=NNc1ccccn1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCOA1 Q15788 1/20 0.74
NCOA3 Q9Y6Q9 1/20 0.74
KMT2A Q03164 6/20 0.70
MEN1 O00255 4/20 0.70
HSP90AA1 P07900 2/20 0.70
SMN1; SMN2 Q16637 7/20 0.68
LMNA P02545 5/20 0.62
GAA P10253 9/20 0.62
MAPT P10636 7/20 0.62
KDM4E B2RXH2 5/20 0.62
HTT P42858 3/20 0.62
TDP1 Q9NUW8 3/20 0.62
L3MBTL1 Q9Y468 3/20 0.62
TP53 P04637 1/20 0.62
ADAM17 P78536 1/20 0.62
POLB P06746 1/20 0.58
HPGD P15428 2/20 0.58
ALDH1A1 P00352 1/20 0.58
GFER P55789 1/20 0.58
NPC1 O15118 5/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12218014 1.00 NCOA1 (0.74) NCOA1NCOA3KMT2AMEN1HSP90AA1
SCHEMBL13779312 0.85 NCOA1 (1.00) NCOA1NCOA3KMT2AMEN1HSP90AA1
SCHEMBL12807528 0.83 MEN1 (0.72) NCOA1NCOA3KMT2AMEN1HSP90AA1
SCHEMBL20982002 0.83 KMT2A (1.00) NCOA1NCOA3KMT2AMEN1HSP90AA1
SCHEMBL20982004 0.83 GAA (0.76) NCOA1NCOA3KMT2AMEN1HSP90AA1
SCHEMBL15742301 0.83 KMT2A (1.00) NCOA1NCOA3KMT2AMEN1HSP90AA1
SCHEMBL18591317 0.83 GAA (0.76) NCOA1NCOA3KMT2AMEN1HSP90AA1
SCHEMBL19425616 0.81 NCOA1 (0.69) NCOA1NCOA3KMT2AMEN1HSP90AA1
SCHEMBL6714010 0.78 MAPT (0.67) KMT2AMEN1HSP90AA1SMN1; SMN2LMNA
SCHEMBL12807532 0.78 KMT2A (0.69) NCOA1NCOA3KMT2AMEN1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040053977-A1 Medicinal uses of hydrazones ALMSTEAD JI-IN KIM (US) 2004-03-18 US claimed
US-6660737-B2 Antihypoxic agents THE PROCTER & GAMBLE COMPANY 2003-12-09 US claimed
US-20030092716-A1 Medicinal uses of hydrazones THE PROCTER & GAMBLE COMPANY 2003-05-15 US claimed
US-20040053977-A1 Medicinal uses of hydrazones ALMSTEAD JI-IN KIM (US) 2004-03-18 US disclosed
US-6660737-B2 Antihypoxic agents THE PROCTER & GAMBLE COMPANY 2003-12-09 US disclosed
US-20030092716-A1 Medicinal uses of hydrazones THE PROCTER & GAMBLE COMPANY 2003-05-15 US disclosed
WO-2002089809-A1 MEDICINAL USES OF HYDRAZONES AND HYDRAZINES THE PROCTER & GAMBLE COMPANY (US) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053977-A1 Medicinal uses of hydrazones PGF, VEGFA, TEK NCOA1 2533/4885NCOA3 3350/4885KMT2A 3683/4885
US-20030092716-A1 Medicinal uses of hydrazones EPOR, VEGFA, HIF1A NCOA1 2149/4885NCOA3 3268/4885KMT2A 4156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.